Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial

Mina Madan, J. Dawn Abbott, Ryan Lennon, Derek Y.F. So, Andrea M. Macdougall, Mary Ann McLaughlin, Vishakantha Murthy, Jacqueline Saw, Charanjit Rihal, Michael E. Farkouh, Naveen L. Pereira, Shaun G. Goodman

Research output: Contribution to journalArticlepeer-review


BACKGROUND: TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to decreased Clopidogrel Response After Percutaneous Coronary Intervention) studied genotype-guided selection of antiplatelet therapy after percutaneous coronary intervention versus conventional therapy with clopidogrel. The presence of CYP2C19 loss-of-function alleles in patients treated with clopidogrel may be associated with increased risk for ischemic events. We report a prespecified sex-specific analysis of genotyping and associated cardiovascular outcomes from this study. METHODS AND RESULTS: Associations between sex and major adverse cardiac events (MACE: cardiovascular death, myo-cardial infarction, stroke, stent thrombosis, and severe recurrent ischemia) and Bleeding Academic Research Consortium (BARC) bleeding at 12 months were analyzed using Cox proportional-hazards models. Among 5276 randomized patients, loss-of-function carriers were observed in ≈36% of both sexes, and >80% of carriers were heterozygotes. At 12 months, after adjustment for baseline differences, risks of MACE (HR, 1.28 [0.97 to 1.68]; P=0.088) and BARC bleeding (hazard ratio [HR], 1.36 [0.91 to 2.05]; P=0.14) were comparable among women and men. There were no significant interactions between sex and treatment strategy for MACE interaction P value (Pint =0.59) or BARC bleeding (Pint =0.47) nor for sex and genotype (MACE Pint =0.15, and BARC bleeding Pint =0.60). CONCLUSIONS: CYP2C19 loss-of-function alleles were present in ≈1 in 3 women and men. Women had similar adjusted risks of MACE and bleeding as men following percutaneous coronary intervention. Genotype-guided therapy did not significantly reduce the risk of MACE or bleeding relative to conventional therapy for both sexes.

Original languageEnglish (US)
Article numbere024709
JournalJournal of the American Heart Association
Issue number12
StatePublished - Jun 21 2022


  • genotype
  • sex differences

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial'. Together they form a unique fingerprint.

Cite this